Articles related to CLINICAL STUDY

Greater adherence to a number of healthy eating patterns was linked to a lower risk of death in this cohort study, which included 44,085 men and 75,230 women from the Health Professionals Follow-Up Study (1986-2020) and the Nurses’ Health Study (1984-2020). These relationships held true for persons who were Hispanic, non-Hispanic Black, and non-Hispanic White, as well as for other racial and ethnic groupings.

This large cohort study evaluated the frequency of 70 long COVID outcomes in unvaccinated individuals with mild COVID infection matched to uninfected individuals and to vaccinated individuals. Anosmia and dysgeusia were the most frequently reported long COVID symptoms with the risk being dramatically increasing at 30 days to 6 months post infection and falling rapidly thereafter. Mild COVID generated an 85% increased risk of cognitive impairment an 80% increased risk of dyspnea and weakness and a nearly 50% increased risk for palpitations. The findings were consistent across all COVID variants and were more marked in adults than children. Vaccinated individuals with breakthrough infection had similar risk for all these outcomes with the exception of dyspnea, for which the risk was lower in vaccinated persons.

Clinically significant anxiolytic and antidepressant benefits were seen in anxious depression patients after TMS in all samples, with average reductions in GAD-7 and PHQ-9 scores of 50% or more. The PHQ-9 scores for both the anxious and nonanxious depression groups improved equally. The worried group, however, scored higher both at the beginning of the study and after TMS, leading to significantly lower categorical rates of response and remission in depressive symptoms. The shift in anxiety and depressive symptoms substantially correlated among individuals who had anxious depression.

The risk of symptomatic intracranial hemorrhage was lower among the 832 patients receiving direct oral anticoagulant treatment in this cohort study involving 33,207 patients with ischemic stroke who received intravenous thrombolysis at 64 centers in Europe, Asia, Australia, and New Zealand when compared to controls who received no anticoagulation. This outcome held true across subgroups and various selection methodologies.

Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.

Yes, you read that right. According to a recent study in Scientific Reports, Chlamydia pneumoniae assaults the central nervous system by traveling up via the nose canal and into the brain. When the bacteria reach the brain, they encourage the production of amyloid beta protein, which is regarded to be a defining feature of dementia and Alzheimer’s disease.